


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:
File Information Unit
Crystal Plaza Three, Room 1D01
2021 South Clark Place
Arlington, VA
Telephone: (703) 308-2733



In re Application of

Application Number

Filed

08/234,145

4-28-94

Paper No. 21

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____,

United States Patent Number 6,657,108, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____.

Related Information about Access to Pending Applications (37 CFR 1.14):

Direct access to pending applications is not available to the public (see 37 CFR 1.14(c) if applicant) but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:

For published applications that are still pending, a member of the public may obtain a copy of:

- the file contents;
- the pending application as originally filed; or
- any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the file contents;
 - the pending application as originally filed; or
 - any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:
 - the pending application as originally filed.

SPS

Signature

Specialized Patent Services

Typed or printed name

Registration Number, if applicable

703-415-1555

Telephone Number

8-20-04

Date

FOR PTO USE ONLY

Approved by: PK

(Initials)

Unit: FIU

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **BRING TO: File Information Unit, Crystal Plaza Three, Room 1D01, 2021 South Clark Place, Arlington, VA.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US006657103B1

(12) **United States Patent**
Kucherlapati et al.(10) **Patent No.:** **US 6,657,103 B1**
(45) **Date of Patent:** ***Dec. 2, 2003**(54) **HUMAN ANTIBODIES DERIVED FROM
IMMUNIZED XENOMICE**(75) **Inventors:** Raju Kucherlapati, Darien, CT (US);
Aya Jakobovits, Menlo Park, CA (US);
Sue Klapholz, Stanford, CA (US);
Daniel G. Brenner, San Mateo, CA
(US); Daniel J. Capon, Hillsborough,
CA (US)(73) **Assignee:** Abgenix, Inc., Fremont, CA (US)(*) **Notice:** This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) **Appl. No.:** 08/923,138(22) **Filed:** Sep. 4, 1997**Related U.S. Application Data**

(63) Continuation of application No. 08/430,938, filed on Apr. 27, 1995, now abandoned, which is a continuation-in-part of application No. 08/234,145, filed on Apr. 28, 1994, now abandoned, which is a continuation-in-part of application No. 08/112,848, filed on Aug. 27, 1993, now abandoned, which is a continuation of application No. 08/031,801, filed on Mar. 15, 1993, which is a continuation-in-part of application No. 07/919,297, filed on Jul. 24, 1992, now abandoned, which is a continuation-in-part of application No. 07/610,515, filed on Nov. 8, 1990, now abandoned, which is a continuation-in-part of application No. 07/466,008, filed on Jan. 12, 1990, now abandoned.

(51) **Int. Cl.⁷** C12P 21/00; A01K 67/027;
C12N 15/63(52) **U.S. Cl.** 800/6; 800/4; 800/18;
435/320.1(58) **Field of Search** 800/4, 6, 18; 435/320.1(56) **References Cited****U.S. PATENT DOCUMENTS**

4,816,397 A	3/1989	Boss et al.	435/68
4,950,599 A	8/1990	Bertling	435/172.3
4,959,313 A	9/1990	Taketo	435/69.1
5,204,244 A	4/1993	Fell et al.	435/69.6
5,545,806 A *	8/1996	Lonberg et al.	800/2
5,545,807 A *	8/1996	Surani et al.	800/2
5,569,824 A	10/1996	Donohower et al.	800/2
5,569,825 A	10/1996	Lonberg et al.	800/2
5,591,669 A *	1/1997	Krimpenfort	800/2
6,150,584 A *	11/2000	Kucherlapati et al.	800/18

FOREIGN PATENT DOCUMENTS

AU	B-15172/95	7/1995
EP	0 298 807 A1	6/1988
EP	0 315 062	5/1989
EP	0 322 240	6/1989
EP	322240	6/1989
EP	0 459 372 A3	5/1991

EP	0 463 151	1/1992
WO	WO 90/04036	4/1990
WO	WO 91/00906	1/1991
WO	WO 91/10741	7/1991
WO	WO 92/03918	3/1992
WO	WO 93/05165	3/1993
WO	WO 94/00569	1/1994
WO	WO 94/02602	2/1994
WO	WO 96/33735	10/1996

OTHER PUBLICATIONS

Bruggeman et al. *PNAS* 82: 6709, 1989.*
Cox, declaration in 5, 545, 806.*
Dorfman, Nickolas A., 1985, "The Optimal Technological Approach to the Development of Human Hybridomas," *Journal of Biological Response Modifiers* 4:213-239.
Taggart et al., 1983, "Stable Antibody-Producing Murine Hybridomas," *Science* 219:1228-1230.
Albertsen, et al., Construction and characterization of a yeast artificial chromosome library containing seven haploid human genome equivalents, *Proc. Natl. Acad. Sci.* 87:4256-4260 (1990).
Aldhous, "Transgenic mice display a class (switching) act," *Science* 262:1212-1213 (1993).
Ayares, et al., "Sequence homology requirements for inter-molecular recombination in mammalian cells," *Proc. Natl. Acad. Sci.*, 83:5199-5203 (1986).
Berman, et al., "Content and organization of the human Ig V_H locus: definition of three new V_H families and linkage to the Ig C_H locus," *EMBO J.*, 7:727-738 (1988).
Bird, et al., "Single-Chain Antigen-Binding Proteins," *Science*, 423-426 (1988).
Blankenstein, et al., "Immunoglobulin V_H region genes of the mouse are organized in overlapping clusters," *Eur. J. Immunol.*, 17:1351-1357 (1987).
Brinster, et al., "Introns increase transcriptional efficiency in transgenic mice," *Proc. Natl. Acad. Sci.*, 85:836-840 (1988).
Brownstein, et al., "Isolation of single-copy human genes from a library of yeast artificial chromosome clones," *Science*, 244:1348-1351 (1989).
Bruggeman, et al., "Human antibody production in transgenic mice: expression from 100kb of the human IgH locus," *European Journal of Immunology*, 21:1323-1326 (1991).
Bruggemann, et al., "Construction, function and immunogenicity of recombinant monoclonal antibodies," *Behring Inst. Mitt.*, 87:21-24 (1990).

(List continued on next page.)

Primary Examiner—Anne M. Wehbe'(74) **Attorney, Agent, or Firm**—Fish & Neave; James F. Haley, Jr.; Jane T. Gunnison(57) **ABSTRACT**

Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.

4 Claims, 18 Drawing Sheets